CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that two abstracts related to its Toll-like Receptor 9 (TLR9) agonist, IMO-2125, were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 14-18, 2010. IMO-2125 is being evaluated for potential applications in chronic hepatitis C virus (HCV) infection. The accepted abstracts include an oral presentation of interim results from a Phase 1 clinical trial which evaluated IMO-2125 in null-responder HCV patients and a poster presentation of gene expression profiles in human peripheral blood mononuclear cells (PBMCs) stimulated with IMO-2125. The abstracts can be accessed through the EASL website, www.easl.ch. In accordance with the EASL embargo policy, the accepted abstract titles are provided below:
